NCT05941936View on ClinicalTrials.gov

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Solid Tumor
Interventions
BIOLOGICAL

LM103

Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.

Trial Locations (1)

300000

RECRUITING

Tianjin Beichen Hospital, Tianjin

All Listed Sponsors
lead

Suzhou BlueHorse Therapeutics Co., Ltd.

INDUSTRY